Address
OrbiMed Advisors LLC
767 Third Avenue
30th Floor
New York, NY 10017
United States
Phone
Website
Recent investment activity
KANDO id: 29979
Corporate information
Founders
Official name
OrbiMed Advisors Limited Liability Company
Registration country
Company type
American investment firm focused on making public and private investments in the healthcare and biotechnology industries.Overview
OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.
Funding rounds
Investment preferences
Investment activity status
Active investor
Selected investments
Displaying 101 - 114 of 114| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
EUSA Pharma Inc | Trans-Atlantic specialty pharmaceutical company which focuses on oncology and critical care | Venture Follow-on investment | |||
|
|
EUSA Pharma Inc | Trans-Atlantic specialty pharmaceutical company which focuses on oncology and critical care | Venture Follow-on investment | |||
|
|
InteKrin Therapeutics Inc | Biopharmaceutical company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders.. | Series C | |||
|
|
MacroGenics Inc | Biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases. | Series C | |||
|
Merrimack Pharmaceuticals Inc | N/A | ||||
|
|
Methylgene Inc | Clinical-stage biopharmaceutical company that develops novel therapeutics for cancer and infectious disease. | N/A | |||
|
Natera Inc | Biotechnology company providing preconception and prenatal genetic testing services. | Venture Initial investment led the round | |||
|
|
Neurogen Corp | N/A | ||||
|
Nutrinia Ltd | Developer of an oral formulation of insulin for intestinal malabsorption in preterm newborns and SBS in infants. | Series D Follow-on investment | |||
|
|
NxStage Medical Inc | Hemofiltration for kidney failure | N/A | |||
|
Tricida Inc | Series C Follow-on investment | ||||
|
|
Tricida Inc | Series B Follow-on investment led the round | ||||
|
|
Tricida Inc | Series A led the round | ||||
|
|
XenoPort Inc | N/A Initial investment |